Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis

Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis

Abstract Dupilumab was approved for treating adult patients with atopic dermatitis (AD) refractory to topical therapy in Japan in April 2018, and self‐injection of dupilumab has been available since May 2019. Subcutaneous self‐injection of medication has benefits for patients and the healthcare syst...

Full description

Bibliographic Details
Main Authors: Makoto Ito, Masahiro Kamata, Takeko Ishikawa, Hideaki Uchida, Shoya Suzuki, Ryosuke Takeshima, Ayu Watanabe, Itsumi Mizukawa, Shota Egawa, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Yayoi Tada
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Journal of Cutaneous Immunology and Allergy
Subjects:
atopic dermatitis
dupilumab
Self‐Injection Assessment Questionnaire
Online Access:https://doi.org/10.1002/cia2.12313

Internet

https://doi.org/10.1002/cia2.12313

Similar Items